Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis

Author： Palmer Andrew   Valentine William   Ray Joshua   Roze Stephane   Muszbek Noemi  

Publisher： Springer Publishing Company

ISSN： 1618-7598

Source： The European Journal of Health Economics, Vol.8, Iss.2, 2007-06, pp. : 161-168

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes

By Neutel Joel M.   Kereiakes Dean J.   Waverczak William F.   Stoakes Kathy A.   Xu Jianbo   Shojaee Ali  

Current Medical Research and Opinion, Vol. 26, Iss. 3, 2010-03 ,pp. : 721-728

Informa Healthcare

Access to resources Recommend Favorite

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension

By Palmer Andrew J.   Valentine William J.   Tucker Daniel M. D.   Ray Joshua A.   Roze Stéphane   Annemans Lieven   Lapuerta Pablo   Chen Roland   Gabriel Sylvie   Carita Paulo   Rodby Roger A.   de Zeeuw Dick   Parving Hans-Henrik   Laville Maurice  

Current Medical Research and Opinion, Vol. 22, Iss. 11, 2006-11 ,pp. : 2095-2100

Informa Healthcare

Access to resources Recommend Favorite

Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31793 patients

By Strutz F.   Bramlage P.   Paar W. D.  

Current Medical Research and Opinion, Vol. 21, Iss. 9, 2005-09 ,pp. : 1433-1440

Informa Healthcare

Access to resources Recommend Favorite

Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 805-808

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting

By Roze Stéphane   Valentine William J.   Evers Thomas   Palmer Andrew J.  

Current Medical Research and Opinion, Vol. 22, Iss. 7, 2006-07 ,pp. : 1415-1424

Informa Healthcare

Access to resources Recommend Favorite